Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acmopatide
- Development stage
- Discontinued
- Lead developer
- Roche
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous
01
Overview
Acmopatide (CT-868) is a once-daily subcutaneous peptide-small molecule hybrid compound that acts as a dual agonist of the glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors. Originally developed by Carmot Therapeutics (subsequently acquired by Roche), acmopatide was designed as a therapeutic agent for type 1 diabetes mellitus, type 2 diabetes mellitus, and obesity. In a Phase 2 trial of adults with type 1 diabetes and obesity, acmopatide demonstrated significant improvements in glycemic control (HbA1c reduction), body weight reduction, and decreased daily insulin requirements without major safety concerns. Despite these positive results, Roche discontinued the development of acmopatide in 2026 to prioritize other pipeline assets, such as enicepatide.
- Other names
- GLP-1/GIP receptor agonist - Carmot Therapeutics
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on acmopatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acmopatide.